These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 32228647)

  • 1. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
    Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
    Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
    Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
    Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
    Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis.
    Chen YH; Chen SH; Hou J; Ke ZB; Wu YP; Lin TT; Wei Y; Xue XY; Zheng QS; Huang JB; Xu N
    Aging (Albany NY); 2019 Oct; 11(21):9478-9491. PubMed ID: 31672930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
    García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
    BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.
    Tronik-Le Roux D; Sautreuil M; Bentriou M; Vérine J; Palma MB; Daouya M; Bouhidel F; Lemler S; LeMaoult J; Desgrandchamps F; Cournède PH; Carosella ED
    Cancer Immunol Immunother; 2020 Jul; 69(7):1237-1252. PubMed ID: 32166404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
    Ghatalia P; Gordetsky J; Kuo F; Dulaimi E; Cai KQ; Devarajan K; Bae S; Naik G; Chan TA; Uzzo R; Hakimi AA; Sonpavde G; Plimack E
    J Immunother Cancer; 2019 May; 7(1):139. PubMed ID: 31138299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Klümper N; Ralser DJ; Bawden EG; Landsberg J; Zarbl R; Kristiansen G; Toma M; Ritter M; Hölzel M; Ellinger J; Dietrich D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap.
    Shi B; Ding J; Qi J; Gu Z
    Int J Med Sci; 2021; 18(9):2063-2075. PubMed ID: 33850477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy.
    Huang T; Peng Y; Liu R; Ma B; Chen J; Wei W; Zhong W; Liu Y; Guo S; Han H; Zhou F; Zhang Z; He L; Dong P
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113106. PubMed ID: 39288623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.
    Zheng W; Zhang S; Guo H; Chen X; Huang Z; Jiang S; Li M
    Cell Commun Signal; 2021 Mar; 19(1):39. PubMed ID: 33761933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
    Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
    Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.